Resultados de investigación

Anàlisis geoquímiques i fotos de visu i microscòpia de les mostres que integren la col·lecció de geostandards del Museu de Geologia Valentí Masachs (UPC Manresa). Análisis geoquímicas y fotos de visu y microscopio de las muestras que integran la colección de geostandares del Museo de Geología Valentí Masachs (UPC Manresa). Geochemical analyses and hand and microscopy pictures of the samples belonging to the geostandards collection of the Valenti Masachs Geology Museum (UPC Manresa). Analyses géochimiques et photographies au microscope et visu des échantillons qui forment la collection de geostandards du Musée de Géologie Valentí Masachs (UPC Manresa)., 1

Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Comment in: Hemophilia Therapy--Navigating Speed Bumps on the Innovation Highway. [N Engl J Med. 2016], The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age <6 years, severe hemophilia A, and no previous treatment with any factor VIII concentrate or only minimal treatment with blood components) were included from 42 sites. Of 303 patients screened, 264 underwent randomization and 251 were analyzed. Inhibitors developed in 76 patients, 50 of whom had high-titer inhibitors (≥5 Bethesda units). Inhibitors developed in 29 of the 125 patients treated with plasma-derived factor VIII (20 patients had high-titer inhibitors) and in 47 of the 126 patients treated with recombinant factor VIII (30 patients had high-titer inhibitors). The cumulative incidence of all inhibitors was 26.8% (95% confidence interval [CI], 18.4 to 35.2) with plasma-derived factor VIII and 44.5% (95% CI, 34.7 to 54.3) with recombinant factor VIII; the cumulative incidence of high-titer inhibitors was 18.6% (95% CI, 11.2 to 26.0) and 28.4% (95% CI, 19.6 to 37.2), respectively. In Cox regression models for the primary end point of all inhibitors, recombinant factor VIII was associated with an 87% higher incidence than plasma-derived factor VIII (hazard ratio, 1.87; 95% CI, 1.17 to 2.96). This association did not change in multivariable analysis. For high-titer inhibitors, the hazard ratio was 1.69 (95% CI, 0.96 to 2.98). When the analysis was restricted to recombinant factor VIII products other than second-generation full-length recombinant factor VIII, effect estimates remained similar for all inhibitors (hazard ratio, 1.98; 95% CI, 0.99 to 3.97) and high-titer inhibitors (hazard ratio, 2.59; 95% CI, 1.11 to 6.00). Patients treated with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitors than those treated with recombinant factor VIII. (Funded by the Angelo Bianchi Bonomi Foundation and others; ClinicalTrials.gov number, NCT01064284; EudraCT number, 2009-011186-88.)., Si, 2016-11-26

First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer., Si

The STARS trial (Stroke Treatment With Acute Reperfusion and Simvastatin) was conducted to demonstrate the efficacy and safety of simvastatin treatment in acute stroke. STARS07 was a multicentre, phase IV, prospective, randomized, double-blind, placebo-controlled trial. Patients with Acute ischemic stroke recruited within 12 hours from symptom onset were randomized to oral simvastatin 40 mg or placebo, once daily for 90 days. Primary outcome was proportion of independent patients (modified Rankin Scale score of ≤2) at 90 days. Safety end points were hemorrhagic transformation, hemorrhagic events, death, infections, and serious adverse events. From April 2009 to March 2014, 104 patients were included. Fifty-five patients received intravenous tissue-type plasminogen activator. No differences were found between treatment arms regarding the primary outcome (adjusted odds ratio, 0.99 [0.35-2.78]; P=0.98). Concerning safety, no significant differences were found in the rate of hemorrhagic transformation of any type, nor symptomatic hemorrhagic transformation. There were no differences in other predefined safety outcomes. In post hoc analyses, for patients receiving tissue-type plasminogen activator, a favorable effect for simvastatin treatment was noted with higher proportion of patients experiencing major neurological recovery (adjusted odds ratio, 4.14 [1.18-14.4]; P=0.02). Simvastatin plus tissue-type plasminogen activator combination seems safe in acute stroke, with low rates of bleeding complications. Because of the low recruitment, the STARS trial was underpowered to detect differences in simvastatin efficacy., Si

Plano medio, de izquierda a derecha, Javier Bello, alcalde de Alcalá de Henares; Rafael Rodríguez-Ponga Salamanca, secretario general del Instituto Cervantes; y Fernando Galván, rector de la Universidad de Alcalá de Henares (UAH), durante la presentación del programa «Lecturas y relecturas. Lecturas actuales de prosas clásicas» en el Instituto Cervantes en Alcalá de Henares.

Plano medio, en la mesa de izquierda a derecha, Javier Bello, alcalde de Alcalá de Henares; Rafael Rodríguez-Ponga Salamanca, secretario general del Instituto Cervantes; y Fernando Galván, rector de la Universidad de Alcalá de Henares (UAH), durante la presentación del programa «Lecturas y relecturas. Lecturas actuales de prosas clásicas» en la sede del Instituto Cervantes en Alcalá de Henares.

Plano medio de Charles-Étienne Lagasse, presidente de la red de Institutos Culturales Europeos (EUNIC) y director general de Wallonie-Bruxelles International, durante la presentación de proyectos de EUNIC en el Instituto Cervantes.

De izquierda a derecha, plano general de Annika Rembe, vicepresidenta primera de la red de Institutos Culturales Europeos (EUNIC) y directora general del Instituto Sueco de Cultura; Jesús Manuel Gracia Aldaz, secretario de Estado de Cooperación Internacional y para Iberoamérica y presidente del consejo de administración del Instituto Cervantes; Charles-Étienne Lagasse, presidente de EUNIC y director general de Wallonie-Bruxelles International; y Rafael Rodríguez-Ponga, vicepresidente segundo de EUNIC y secretario general del Instituto Cervantes, durante la presentación de los proyectos de EUNIC en el Instituto Cervantes.

Primer plano de asistentes a la exposición «Juan Gris: Dibujos satíricos» en el Instituto Cervantes de París.

En la mesa, de izquierda a derecha, plano general de Emilio Ferré, coleccionista; Juan Manuel Bonet, director del Instituto Cervantes de París; y Serge Fauchereau, crítico de arte, durante la presentación de la exposición «Juan Gris: Dibujos satíricos» en el Instituto Cervantes de París.